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Trypanosoma brucei rhodesiense and T. brucei gambiense, the causative agents of
Human African Trypanosomiasis, are transmitted by tsetse flies. Within the vector,
the parasite undergoes through transformations that prepares it to infect the human
host. Sequentially these developmental stages are the replicative procyclic (in which the
parasite surface is covered by procyclins) and trypo-epimastigote forms, as well as the
non-replicative, infective, metacyclic form that develops in the vector salivary glands.
As a pre-adaptation to their life in humans, metacyclic parasites begin to express and
be densely covered by the Variant Surface Glycoprotein (VSG). Once the metacyclic
form invades the human host the parasite develops into the bloodstream form. Herein
the VSG triggers a humoral immune response. To avoid this humoral response, and
essential for survival while in the bloodstream, the parasite changes its cover periodically
and sheds into the surroundings the expressed VSG, thus evading the consequences
of the immune system activation. Additionally, tools comparable to quorum sensing are
used by the parasite for the successful parasite transmission from human to insect. On
the other hand, the human host promotes clearance of the parasite triggering innate
and adaptive immune responses and stimulating cytokine and chemokine secretion. All
in all, the host–parasite interaction is extremely active and leads to responses that need
multiple control sites to develop appropriately.
Keywords: human African trypanosomiasis, variant surface glycoprotein, dynamic interaction, antigenic diversity,
host response
INTRODUCTION
Few microorganisms are responsible for the major parasitic diseases of the XX and XXI centuries,
trypanosomes among them. HAT, or sleeping sickness, is a severe meningoencephalitic disease that
develops after an acute lymphatic infection. The estimates of “years lived with disability” for HAT,
according to the Global Burden of Disease, range from 2,000 to 25,000 per year, with about 30
African countries affected by the ailment (Sutherland et al., 2015). However, the rate of under-
reporting may reach numbers higher than 40%, meaning that the accurate figures of people at risk
are underestimated (Fèvre et al., 2008).
Abbreviations: CCA, cis-aconitate; CNS, central nervous system; CSF, cerebrospinal fluid; DOT, disruptor-of telomeric
silencing; ESAGs, expression sites associated genes; HAT, human African trypanosomiasis; PAD, protein associated with
differentiation; SIF, stumpy induction factor; TLF, trypanolytic factors; TLTF, trypanosome triggering factor; VSG, variant
surface glycoprotein.
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Similar to other microbes and parasites, trypanosomes
challenge the immune system and induce a host response. This
parasite–host interaction can produce either a poor immune
response, with a consequent devastating hyper-infection, or
an exaggerated life threatening immune response, also with
overwhelming consequences. To be successful, the parasite needs
to poise its behavior between these two extremes, avoiding
indiscriminate killing of the host and still escaping destruction
by the immune system. Trypanosome achievement has been to
develop successful means of evading the consequences of the
immune system activation and this might be an outcome of
the time constraints and periods shared with humans over their
evolution for many million years (Steverding, 2008; Cnops et al.,
2015).
Except for Trypanosoma cruzi, that invades host cells and is
thus an intracellular pathogen, trypanosomes are extracellular
parasites. When infective trypanosomes invade the bloodstream,
a humoral immune response is usually triggered. However,
T. brucei parasites successfully eludes the adaptive immune
response through the expression of the antigenic VSG. Although
it might be contradictory to use the main antigenic molecule
exposed in the surface of the parasite as a protective tool, the
VSG expressed in the parasite membrane is constantly shed and
renewed by means of re-arrangements in the genome. Covering
the cell with a frequently changed “protective coat” represented
by the VSG allows the parasite to avoid detection by host
antibodies (Horn, 2014).
Switching to a new VSG coat thus constitutes a central
mechanism for the effective evasion of the mammalian immune
system (Horn and Mcculloch, 2010). Additionally, a mechanism
analogous to quorum sensing contributes to the successful
parasite transmission from mammal to insect (Seyfang et al.,
1990; Morrison, 2011). The host activates innate immunity and
cytokine and chemokine secretion to trigger the clearance of
the parasite. This all means that the interaction between the
mammalian host and the parasite is extremely active. Herein,
we will briefly discuss the focused strategy used by the parasite
and question whether or not there is a truly developed host
response, since by using the VSG-switch to facilitate the escape of
a subpopulation of trypanosomes from antibody-mediated killing
the parasite circumvents the host immune system.
DIVERSITY OF TRYPANOSOMA SPECIES
AND HOSTS
Most species of trypanosome are incompetent to infect man; they
infect animals, mainly through their natural insect vector, the
tsetse fly. The trypanolytic protein apolipoprotein-L1 and two
protein complexes or TLF present in human serum (TLF1 and
TLF2) provide innate resistance and normally prevent human
infections (Pérez-Morga et al., 2005; Molina-Portela et al., 2008;
Capewell et al., 2015).
Nevertheless, T. brucei gambiense and T. brucei rhodesiense,
that belong to the T. brucei (b.) group (subgenus Trypanozoon),
are the species that cause HAT. Both species express mechanisms
that overcome and neutralize the function of TLF1 and TLF2
factors. In T. b. rhodesiense the serum resistance associated gene,
which is a truncated VSG, confers resistance to lysis. In T. b.
gambiense a more sophisticated system performs this task. It
involves a specific truncated VSG (TgsGP), a reduced binding
affinity of its receptor for TLF and an increased cysteine protease
activity (De Greef et al., 1992; Xong et al., 1998; Kieft et al.,
2010; Stephens and Stephen, 2011; Capewell et al., 2015). Of note,
several populations of non-human primates display resistance
to infection when challenged with T. b. gambiense and T. b.
rhodesiense (Capewell et al., 2015).
Trypanosoma brucei rhodesiense causes the more virulent form
of HAT (East African or Rhodesian African sleeping sickness).
The Rhodesian African sleeping sickness is zoonotic and rare;
patient deaths often occur within a few months. The West
African or Gambian African HAT disease caused by T. b.
gambiense displays long latency and chronicity (Franco et al.,
2014). For this latter form of disease human beings are the
main reservoir and transmission agent within the life cycle of
the parasite. Unfortunately, there is neither a vaccine nor a
recommended drug available to prevent any (West or East)
African trypanosomiasis (La Greca and Magez, 2011).
Blood-sucking infected female tsetse flies (genus Glossina
spp.; Steverding, 2008) transmit HAT. Within the vector,
procyclic parasites proliferate and the parasite goes through
transformations until reaching the metacyclic stage, i.e., the
infective form for the human host. The metacyclic form that
develops in the vector salivary glands may be inoculated
by the tsetse fly with its saliva into a mammalian host
(Franco et al., 2014). HAT is infrequently transmitted by blood
transfusion (Franco et al., 2014). The disease causes infertility
and miscarriage in humans; thus, transmission by placental
means is uncertain. Still, the guidelines and protocols related to
HAT stress that pregnant women and newborns from infected
mothers should be systematically checked for HAT (Lindner and
Priotto, 2010; Franco et al., 2014). Oral, blood–blood (e.g., by
sexual contact), and iatrogenic transmission (with contaminated
needles) could have an occasional impact (Franco et al., 2014).
Mechanical transmission by biting insects that suck pathogens
from one host (Gruvel, 1980) and prior to swallowing its blood
inoculate them with the saliva into another host (Foil, 1989),
might be relevant for transmission of pathogenic trypanosomes
that do not infect humans, but its epidemiological impact for the
human disease is difficult to assess.
Two African trypanosome subgenera, Nannomona and
Duttonella (T. congolense and T. vivax, respectively), cause the
cattle disease nagana (Duffy et al., 2009; Morrison et al., 2009).
T. evansi (subgenus Trypanozoon) infects mammals including
horses, mules, camels, buffalo, cattle and deer and produce
a disease called surra (mal de cadeiras), of great economic
importance in many geographic areas. In fact, in Africa, Asia,
and South America thousands of animals die from T. evansi
or T. vivax infection every year (Camargo et al., 2015).
T. equiperdum (subgenus Trypanozoon) infects equines under
natural conditions; by venereal transmission it may also cause
a disease of equines called dourine (Desquesnes et al., 2013).
T. evansi (monomorphic) and T. equiperdum (monomorphic
but occasionally pleomorphic) are morphologically similar to the
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slender forms of T. b. brucei, as well as of T. b. rhodesiense and
T. b. gambiense (Blacklock and Yorke, 1993; Brun et al., 1998).
The information about the host response in infections produced
by these veterinarian parasites is limited (Lemos et al., 2008;
Camargo et al., 2015); therefore, the present review deals mostly
with the human infecting trypanosomes that cause HAT.
CLINICAL PRESENTATION OF HUMAN
AFRICAN TRYPANOSOMIASIS
In HAT caused by members of the T. brucei group, i.e., T. b.
rhodesiense and T. b. gambiense, the comprehension of the role
played both by the parasite and the host during the host–parasite
interaction is essential to understand the clinical performance of
the disease.
The sickness has two clear cut clinical stages, i.e., a
hemolymphatic initial systemic stage and a second phase
characterized by the invasion of the brain by parasites. This
encephalitic stage involves sensory, motor and psychiatric
disturbances, with alterations of sleep representing the most
typical manifestations.
The clinical presentation of HAT is thoroughly described by
Vincendeau and Bouteille (2006) and I will briefly summarize its
main steps. Figure 1 reviews the stages that portray the clinical
symptoms of HAT. The tsetse bite produces a painful reaction
characterized by local erythema, heat, edema, and tenderness that
leads to the appearance of the chancre. This is an ulcer where
the parasites are present and it disappears after 2 or 3 weeks.
Thereafter the disease evolves into the successive phases that
characterize its clinical phases (Sternberg, 2004; Kennedy, 2013).
The Hemolymphatic Stage I
Shortly after being infected, the patient enters the hemolymphatic
stage I, a phase in which the disease is often undiagnosed
and, therefore, untreated. Intermittent fever episodes often
occur as a consequence of the successive cyclical waves of
trypanosome parasitemia. However, febrile occurrences cannot
be considered as useful diagnostic elements since they might
be completely absent. Adenopathy, splenomegaly and even liver
disturbances signal the invasion of the reticuloendothelial system
by trypanosomes. Skin rashes and severe pruritus with scratching
skin lesions might become unbearable for the patient and painful
lymph nodes might also occur at this stage (Sternberg, 2004;
Kennedy, 2013).
The Meningoencephalitic Stage II
The meningoencephalitic stage II is an insidious phase that
appears slowly over a period of months or years. The parasites
cross the blood–brain barrier and infect the CNS, causing
disturbances to the patient’s sleep pattern, as well as confusion
and trouble with motor and mental coordination. Fever spikes
common to the hemolymphatic stage I might still be present.
Abnormal quantities of macrophages enter the CSF and non-
specific perivascular inflammatory cell infiltrates occur in the
leptomeninges and white matter, with a pronounced activation
of microglia and astrocytes (Sternberg, 2004; Kennedy, 2013).
The broad spread of the meningeal inflammation to specific
CNS locations leads to the appearance of the neurological
symptoms common to HAT. For example, invasion of the
median eminence by parasites may be the cause of sleep-wake
abnormalities. At the terminal phase of the disease, disturbances
in consciousness and the development of dementia with
incoherence, double incontinence and seizures are consequences
of CNS demyelination and atrophy (Cnops et al., 2015). The
patient dies by heart failure or by encephalitis in a state of
cachexia and physiological collapse (Sternberg, 2004; Kennedy,
2013).
TRANSMISSION BIOLOGY OF HUMAN
AFRICAN TRYPANOSOMIASIS
To cope with the complexity of events involved in the host–
parasite interaction trypanosomes use a focused strategy that
includes the development of distinct life stages to adapt
themselves to the environment they encounter (Vickerman, 1965,
1985; Matthews and Gull, 1994).
During the active interaction between the host and the parasite
the active balance between slender and stumpy trypanosome
forms play key roles in infection and transmission as is
depicted in Figure 2. That is, in the bloodstream, the parasite
proliferates (slender parasite forms with asynchronous life cycle)
and eventually reaches the G1/G0 cell cycle phase and becomes
arrested at the non-proliferative, transmissible, stumpy (G0
arrested, synchronous differentiated) forms (Vickerman, 1965,
1985), to be transmitted to the vector. Herein I will briefly
describe the events that characterize the human host–parasite and
vector-parasite interfaces.
Bloodstream Parasites
What happens at the cellular level, which mechanisms and
which molecules are involved in the host–parasite interaction?
The answer is so far focused on the VSG (see Figures 3
and 4). The VSG is abundantly expressed on the membrane
of parasites belonging to the genus Trypanosoma, being the
predominant surface antigen of African trypanosomes. It is
highly immunogenic, and one of the main components of the
molecular interface that mediates the host–parasite interaction.
Exposure of the VSG coat at the surface of trypanosomes,
rather than being a tool to avoid the immune system, challenges
it to produce a lytic antibody response (Pays et al., 2001).
In fact, via the complement system, VSG-specific antibodies
facilitate efficient opsonization and lysis of parasites expressing
the coat against which the response was triggered (Figure 4).
Trypanosomes avoid detection by host antibodies by recurrently
switching to new VSG coats (Horn and Mcculloch, 2010);
i.e., once antibody titer increase, the vast majority of parasites
are eliminated and only cells with distinct VSG coats survive
(Figure 3, Horn, 2014).
Antigenic variation of T. brucei was originally described in
Franke (1905). However, an understanding of the evolution and
expression (or not) of VSG by each parasite, the variety of the
expressed VSG, as well as the range of sequence similarities
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FIGURE 1 | Clinical presentation of HAT. The painful (infected) tsetse bite leads to the appearance of the so-called chancre. Two or three weeks later the disease
evolves into two successive clinical stages. The hemolymphatic stage I is characterized by the appearance of intermittent fever episodes, adenopathies,
splenomegaly, and even hepatic disturbances. Painful lymph nodes also occur at this stage. The meningoencephalitic stage II appears slowly over a period of
months or years, depending on the infecting trypanosome. The parasites cross the blood brain barrier to infect the CNS, causing the appearance of the neurological
manifestations characteristic of HAT, like disturbance to the patient’s sleep patterns, confusion and difficulty with coordination. At the terminal phase of the disease,
disturbances in consciousness and the development of dementia with incoherence, double incontinence and epileptic seizures are common.
among the VSGs expressed by strains and isolates is far from
complete (Cross et al., 2014). Current information regarding
VSGs relies on data obtained from the TREU927 strain (Cross
et al., 2014), and the partial catalog of VSG genes is described
in: http://tritrypdb.org/common/downloads/release-5.0/, http://
www.genedb.org/Homepage/Tbruceibrucei927
A repertoire of hundreds of VSG genes with a single
active transcription site, always at the end of a chromosome
immediately adjacent to the telomere, has been described in
the parasite genome (Pays et al., 2001; Horn and Mcculloch,
2010). The new VSG to be expressed and become active must
be copied into the single transcribed locus by DNA repair
processes. Additionally, a novel VSG gene can be activated by
the so called allelic exclusion mechanism. This is a coordinated
transcriptional switch that does not produce detectable changes
in the DNA sequence, and maintains singular expression (Horn,
2014). This permits a continuous stochastic switching of VSG
genes at high rates per cell generation, depending on strain and
parasite growing conditions (Turner and Barry, 1989; Turner,
1997). Incomplete genes or pseudogenes, which exist as single
dynamic and highly mutated copies with a strong codon-usage
bias, predominate (ca 80%) on the VSG-genome (Cross et al.,
2014).
The VSG role as a protective “cell coat” is activated in the tsetse
fly salivary gland (before infecting the human host), functions
during the bloodstream mammalian infectious cycle and is
inactivated upon return to the tsetse fly midgut. Bloodstream
parasites express only one VSG coat at a time. Under the pressure
to express a different VSG, a repressive gradient extends from
the chromosome end, shutting down the active VSG expression
site (Horn and Mcculloch, 2010). The silencing of this expression
site triggers trypanosomes to move on from the proliferative
(bloodstream-stage) to the non-proliferative form, as a pre-
adaptation for life in the insect (Figures 3 and 4).
It is not completely clear how silencing is produced.
Chromatin remodeling triggers the silencing to initiate the
FIGURE 2 | The changing aspects of VSG expression. Trypanosomes
oscillate between distinct life stages. Metacyclic (VSG [+]) parasites become
proliferative slender (VSG [+]) forms in the blood stream, reach G1/G0 phase
and differentiate to non-proliferative, transmissible, stumpy, G0 arrested, VSG
[+] forms. Stumpy forms only transform efficiently within the tsetse midgut to
procyclic epimastigote forms (VSG [−]). VSG is constantly changed in each
transmission cycle. This strategy represents an advantage for the parasite that
the human immune system cannot control and thus warrants the parasite
successful evasion of the immune system surveillance.
change of trypanosome performance from proliferative to non-
proliferative. The success of this event depends on the function
of a DOT histone methyltransferase (DOT1B; Figueiredo et al.,
2008) together with attenuation of the expression produced at
some VSG ESAGs (Hertz-Fowler et al., 2008). Furthermore, it has
been proposed that some ESAGs could function as ‘sensors’ that
cue trypanosomes to become quiescent when the expression site
shuts down (Figures 3 and 4, Batram et al., 2014).
The VSG coat is “fluid” and permits a high rate recycling. VSG-
switch and coat exchange starts by dilution during cell division,
Frontiers in Microbiology | www.frontiersin.org 4 December 2016 | Volume 7 | Article 2126
fmicb-07-02126 December 23, 2016 Time: 14:1 # 5
Ponte-Sucre Trypanosoma brucei–Host Dynamic Interaction
FIGURE 3 | Proposed steps on Slender, Stumpy, Procyclic progression. Framework for the successive progression of trypanosomes from slender to stumpy
to procyclic stages. The figure summarizes the data proposed by Engstler and Boshart (2004), Engstler et al. (2007), Figueiredo et al. (2008), Hertz-Fowler et al.
(2008), Field and Carrington (2009), Horn (2014), and Mony and Matthews (2015).
FIGURE 4 | Overview of the lively host–parasite-vector interaction in Trypanosoma brucei infections. The figure summarizes the dynamics of host–parasite
interaction emphasizing the role of the immune system both of the human host and the vector. For details please see main text.
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with cells dividing approximately every 6 h and shedding and
turnover being relatively much slower (Seyfang et al., 1990).
In the meantime, the coat is cleansed of antibodies, aided by
the vigorous directional cell motility mediated by the flagellum
(Engstler et al., 2007; Horn, 2014) and endocytosis at the flagellar
pocket (Field and Carrington, 2009; Horn, 2014). In conclusion,
the role of VSG at the human host–parasite interface is extremely
active. The reiteration of VSG function (expression-shedding)
trigger complex responses that in the end might signify the
exhaustion of the immune system, the survival of the parasite and
the transmission to the vector (Figures 3 and 4).
Vector Parasites
Stumpy forms only differentiate efficiently to procyclic forms
within the tsetse midgut (Vickerman, 1985; Matthews and Gull,
1994), despite their exposure to the acidic pH environment and
the action of proteases (Nolan et al., 2000). In the tsetse fly
procyclic forms replace (in a coupled process) the VSG coat by
procyclins, molecules that do not protect the parasite from lysis
by serum components; this means that if differentiation to the
procyclic form occurs at the wrong time and place, i.e., within the
mammalian host, the parasites would definitively die (Figures 3
and 4, Wenzler et al., 2016).
High concentrations (>3 mM, higher than expected in the
tsetse midgut) of citrate or CCA induce in vitro the differentiation
of bloodstream form trypanosomes to procyclic forms (Brun
and Schonenberger, 1981; Hunt et al., 1994). Also, a drop
in temperature from 37 to 20◦C, similar to that encountered
by trypanosomes when sucked into the tsetse flies’ midgut,
induces the reversible expression of procyclins on the surface
of trypanosomes and increases (stumpy form) trypanosome
sensitivity to CCA (down to µM concentrations, Engstler and
Boshart, 2004). This suggests that CCA levels present within
the tsetse fly blood-meal could be physiologically relevant as the
parasite reaches the digestive tract of the tsetse fly at dawn or
sunset when temperatures are mild.
Based on these data, Engstler and Boshart (2004) proposed
a hierarchical model with three steps that sequentially regulate
differentiation once transmission to the vector (or drop in
temperature) occur (Figure 3). They base their model on the
fact that the order of events strictly depends on the “out of
homeotherm” information provided by the cold shock. This
initial (first step) triggering signal (or step) promotes the function
of a surface system that permits “routing” of the procyclins
to the surface (only in stumpy form parasites and transiently
coexisting with VSG). The next steps need the increased (>1000-
fold) sensitivity of parasites to the differentiation chemical signal
(CCA or citrate), and a concomitant expression of surface
receptors for this signal (Engstler and Boshart, 2004). Although
all the data is not yet available to confirm the role of CCA
and citrate in parasite differentiation, Engstler and Boshart
(2004) suggest that CCA and citrate could be mimics of a yet-
unidentified compound or activation mechanism present in the
vector.
The nature of the molecule responsible for the transmission
of the CCA differentiation signal has thus been elusive. However,
a gene family encoding surface carboxylate transporters known
as PAD proteins (proteins associated with differentiation,
PAD1 and PAD2), expressed in stumpy forms but not
in slender forms, share properties that make them good
candidates to perform this function. PAD proteins are
expressed on the surface of stumpy-form parasites present
in the bloodstream. At least PAD2 is thermoregulated, its
expression is confined to the parasite’s flagellar pocket region
at 37◦C and spreads to the cell surface at 20◦C; finally,
inhibition of PAD expression by the use of RNAi diminishes
CCA-induced differentiation and eliminates CCA-sensitivity
under cold-shock conditions (Brun and Schonenberger, 1981;
Engstler and Boshart, 2004; Dean et al., 2009). This suggests
that PAD proteins may act in coordination with the CCA
signal system, providing stringent control of differentiation
(Figure 3).
Exposure to proteases or pH stress in the tsetse midgut
might also participate in triggering differentiation, either in
a complementary or a parallel manner (Rolin et al., 1998;
Sbicego et al., 1999). Newly enclosed tsetse flies (teneral) have
an immature immune system and are less prone to be infected
by trypanosomes, when compared with mature adults (Aksoy
et al., 2016). In experimentally infected mature tsetse flies, genes
related with DNA/RNA binding, protein phosphorylation, and
initiation of transcription, as well as with cytoskeleton and actin
binding cell-remodeling functions are upregulated. Signaling
pathway (immune deficiency) genes related with the immune
system (Kenny and Imd) and Toll (cactus, dorsal/dif, DEAF-1)
are also upregulated. On the other hand, major gut enzyme
transcripts (trypsins and chymotrypsins) and those related to
the peritrophic matrix barrier formation (peritrophins, serine
protease 6, serine endopeptidase, and hsp60) are down regulated.
These facts suggest that levels of effector molecules present in the
gut at parasite arrival may interfere with parasite colonization
or survival. Additionally, they suggest that trypanosome-
mediated inhibition of peritrophic matrix functions might reduce
the action of the vector immune system and facilitate the
translocation of the parasite into the ectoperitrophic space where
parasites reside in infected flies (Figures 3 and 4, Aksoy et al.,
2016).
Additionally, the release of the parasite VSG into the
midgut of the tsetse fly supports successful colonization of
the gut. Free VSG induces a decreased expression of a micro
RNA (mir-275). In Aedes aegypti mir-275 is linked to gut
function and blood digestion processes (Bryant et al., 2010).
It also interferes with the Wnt-signaling pathway and the
Iroquois/IRX transcription factor family (Cavodeassi et al.,
2001; Lucas et al., 2015). The Wnt-signaling pathway mediates
in eukaryotes cell proliferation, cell-to-cell communication
and embryonic development; in the adult mosquito, it is
involved in fat body secretory processes (Logan and Nusse,
2004). The Iroquois/IRX family regulates embryonic and larval
development mechanisms in Drosophila. The integrated action
of these processes compromises midgut homeostasis and the
integrity of the semipermeable, chitinous barrier that lines
the peritrophic matrix (Aksoy et al., 2016), thus illustrating
how active the vector-parasite interaction is (Figures 3
and 4).
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PARASITE-HUMAN HOST INTERACTION
The following sections deal with the tools that the parasite uses to
evade the consequences of the human immune system activation,
and that the human host uses to promote the successful clearance
of the parasite.
The Role of Parasite and Host Genetics
The genetic variation of the parasite influences the outcome of
the disease. This depends on the specific parasite involved in
causing it. In fact, pathogenesis is strain specific, at least partially,
and may involve different host mechanisms. For example, T. b.
rhodesiense causes the acute HAT disease and T. b. gambiense, the
more chronic infection (Barrett et al., 2003). Most information
obtained up to date related to the role of parasite genetics in
the outcome of the disease has been described in experimental
infections made in animals; the results suggest that the expression
of trypano-tolerance or the existence of trypano-tolerant hosts
(mammals that remain infected but do not display the full-
blown disease) are the consequence of the performance of specific
genetic loci.
In fact, trypano-tolerance can be understood as the reduction
of disease pathogenic consequences. The genetic loci (called
QTL) involved in this phenomenon have been described in cattle
and in experimental models of infected mice (Morrison et al.,
1978; Murray and Morrison, 1979; Murray et al., 1981, 1982;
Kemp et al., 1997; Hill et al., 2015). QTLs identified in cattle
do not overlap completely with those described in mice, and
are much larger; however, both share IL-10 and TNF-α genes as
related to mice and cattle susceptibility. These facts have been
useful to understand genetic and immunological background
of infection produced by trypanosome species in non-primate
mammals, but still extrapolation to what occurs in human beings
is not yet straight forward.
In fact, in human, the definition of trypano-tolerance has
been questioned, although reports on asymptomatic carriers and
spontaneous cure have been published (Bucheton et al., 2011).
For example, in HAT caused by the gambiense strain (considered
as invariably fatal), cases of self-cure in untreated patients have
been described, although accurate diagnostic tools were not
available at the time (revised by Jamonneau et al., 2012). In
studies performed in mangrove areas of coastal Guinea, high
levels of IL-10 and low levels of TNF-α have been associated
with an increased risk to suffer HAT, whereas high levels of IL-8
were associated with disease control (Ilboudo et al., 2014). Recent
data from patients that refused to receive chemotherapy and were
monitored for periods from 5 to 15 years demonstrated parasite
clearance, as observed using follow-up tools such as microscopy
and polymerase chain reaction. Most of the patients became
progressively negative to trypanosome variable antigens, and
expressed milder serological responses (Jamonneau et al., 2012).
This means that whether trypano-tolerance in humans is related
to intrinsic host or parasite factors, or relies on genetic grounds or
on heavy host-T-cell immunity, or on parasite virulence factors,
or on a combination of these, remains to be determined.
Finally, it is well known that clinical outcomes of “mild”
and “severe” T. b. rhodesiense HAT show a correlation with the
geographical area from which patients come (Hide and Tait,
1991). This is so for example for Malawi and Uganda (MacLean
et al., 2004), but also for restricted geographical areas of Uganda
(MacLean et al., 2007). Whether or not this relies on a trypano-
tolerant phenotype in which the host immunology is determinant
must be further analyzed (Morrison et al., 2010).
Parasite Tools to Modulate the Host
Response in Human African
Trypanosomiasis
Quorum Sensing
Replication of slender forms present in the blood of infected
hosts increases the parasitemia. This does not occur ad infinitum;
trypanosomes control their levels within mammalian hosts.
An equilibrium exists –at any time during the infection- as
cell proliferation should be enough to guarantee infection
transmission without surpassing the balance that would destroy
the host, at least at early phases of disease. The initial infecting
parasites may be cleared by the immune system; but as, we
have previously learned, a small proportion of the trypanosome
population switches coats and these parasites with a different
antigenic specificity at their surface escape from the immune
system and remain in the bloodstream long enough to allow
a successful transmission to new hosts (Figures 3 and 4,
Vincendeau and Bouteille, 2006; Horn and Mcculloch, 2010;
Morrison, 2011; Horn, 2014).
Cells, including trypanosomes, are able to sense their
environment and respond accordingly. In fact, differentiation of
slender to quiescent, stumpy bloodstream forms is an individual
event that occurs independently of the host, even in the absence
of an immune response (Seed and Sechelski, 1988; Vassella et al.,
1997). So, even in vitro, pleomorphic strains of trypanosomes
undergo differentiation into stumpy forms once a cell density
is reached. These facts suggest the existence of a density signal
that would help to arrest growth of parasites to hamper their
further proliferation (Hesse et al., 1995; Reuner et al., 1997;
Vassella et al., 1997), thus working like a quorum sensing
mechanism. This parasite–parasite signaling system, as well as
the fact that at peak parasitemia the plasma from infected animals
inhibits trypanosome proliferation, suggests that a secreted factor
could work like the molecule that controls parasite switch from
proliferation to differentiation (Figures 3 and 4, Mony and
Matthews, 2015).
Trypanosomes (pleomorphs and monomorphic) secrete a
soluble, low molecular weight, heat stable factor/s termed SIF.
This is a molecule proposed to be segregated by slender form
parasites that accumulates in the culture medium/bloodstream,
upon increasing parasite density. It is proposed to function as a
slender to stumpy trigger molecule that acts through autocrine
mechanisms (Vassella et al., 1997). Although the identity and
mechanism of action of SIF are still not completely elucidated,
its effector systems seem to include cAMP or hydrolysis products
of cAMP (Vassella et al., 1997; Laxman et al., 2006); however,
controversial recent results using the chemical inducer (8-cPT-
cAMP/AMP) ruled out the use of the canonical pathway of cAMP
(Laxman et al., 2006). Although most of the data needs to be
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validated, it suggests that several protein families are implicated
in the control of stumpy formation (Mony and Matthews, 2015).
This includes networks that either work to retain the slender
form of the parasite or promote stumpy form differentiation
mimicking a starvation like signal. This signaling further activates
protein kinases that induce G1/G0 arrest; protein phosphatases
that regulate protein kinase activities, inactivate slender retainers
and deactivate inhibitors of stumpy differentiation; reactivates
mitochondrial metabolism and leads to the regulation of genes
needed for stumpy form maintenance and differentiation to
procyclic forms (Figures 3 and 4, Mony and Matthews, 2015).
A detailed description is beyond the scope of this review but this
mechanism has been thoroughly analyzed previously (Mony and
Matthews, 2015).
Antigenic Diversity
As already mentioned, due to the mechanism of antigenic
variation the expression of a novel VSG constitutes the main
way of evading a constant attack by the immune system. Thus,
individual cells switch the identity of the expressed VSG at a low
frequency, to be selected (or not) by the host immune response.
If the VSG is novel, it acts as a protective barrier by shielding the
cell from innate and adaptive immune factors, and trypanosomes
proliferate, thus maintaining the infection; this happens until
an overwhelming titer of antibodies recognize the expressed
VSG (Pays, 2005). If VSG doesn’t switch, or if the new VSG
is not novel, the parasite will be killed. Additionally, antibodies
produced by the host are eliminated from the parasite surface
by the concerted action of clathrin-dependent endocytosis of
antibody-bound surface proteins and antibody degradation that
aids immune evasion while the host antibody titer is low
(O’Beirne et al., 1998; Hall et al., 2003; Manna et al., 2013).
Host Tools to Tackle the Infection in
Human African Trypanosomiasis
Innate Immunity
The interaction between trypanosomes and their mammalian
hosts triggers events that sequentially activate innate and specific
immunity. The efficient presentation of parasitic antigens leads
to the activation of T and B cells and the development of strictly
regulated effector mechanisms. However, since trypanosomes
have efficiently “learned” to cope with the host immune
system, the effectivity of the triggered responses is limited and
the parasites are seldom completely eliminated thus inducing
immunopathological phenomena that end up in tissue damage
(Figure 4, Vincendeau and Bouteille, 2006).
In HAT, when trypanosome enters the skin of the mammalian
host upon the tsetse fly bite, trypanosome proliferation induces
a local skin reaction that constitutes the first protection to be
developed by the host. This skin reaction eventually transforms
in an ulcer (the chancre). The lymphatic vessels surrounding it
already have dividing trypanosomes ca. 5 days after the bite and a
couple of days before the complete establishment of the chancre.
Eventually the response is mainly mediated by T cells (specially
TCD8+, see Figure 4, Vincendeau and Bouteille, 2006).
Although complement activation is commonly detected
at this initial stage of HAT, it is also usual to observe
“hypocomplementemia” (Devine et al., 1986). This has been
attributed to an activation (and eventual depletion) of the
complement pathway directly by the parasites, as has been
demonstrated in T. b. gambiense exposed to human serum.
The complement activation occurs without triggering a lytic
activity, the reason being that the cascade does not continue
beyond the establishment of C3 convertase on the trypanosome
surface (Devine et al., 1986). Also, a time dependent decrease
in complement activity has been observed during trypanosome
infections by T. b. gambiense or T. b. rhodesiense (Matthews et al.,
2015).
This all means that the initial immune response is complex. In
fact, parasite clearance may occur via antibody-mediated lysis due
to the activation of the classical complement pathway (through
specific antibodies against trypanosomes), or via the alternative
complement pathway, independent of specific antibodies, (on
procyclic, VSG [-] trypanosomes). Of note, VSG isolated from
T. b. brucei activates the classical complement pathway in an
antibody-independent fashion [Figure 4, (Musoke and Barbet,
1977)]. On the other hand, immune complexes constituted by
antibodies specific to trypanosomes (e.g., anti- VSG antibodies)
may arise (Russo et al., 1994; Vincendeau and Bouteille, 2006).
These immune complexes, together with complement pathway
activation, promote tissue damage that might induce aggressive
effects including thrombosis and renal glomerular damage
(Hasselbalch et al., 1985; Bruijn et al., 1988; van Velthuysen et al.,
1994).
The activation of the complement pathway may lead to
the appearance of soluble fragments. These could include
the C3a and C5a anaphylatoxins, and the complex C567.
Some of these fragments may trigger chemotactic responses
by neutrophils and monocytes, as well as the release of
neurotransmitters involved in triggering an increase on
vascular permeability that aids the initial inflammatory
response to the chancre. Finally, natural killer cells might
also participate in the initiation of the inflammatory response
through the synthesis of cytokines and chemokines like
IFN-γ and TNF-α (Figure 4, Vincendeau and Bouteille,
2006).
Information about the role of cell mediated immune responses
is mainly described in animal models of experimental infections.
The results suggest that neutrophils and T and B lymphocytes
infiltrate and predominate in the local skin reaction, the former
in the early days whereas the latter permeate the chancre at 5–
7 days post-infection, with CD8+ T cells predominating in the
chancre at even later stages (Mwangi et al., 1990; Vincendeau
and Bouteille, 2006) and increased density of CD4+ and CD8+
T cells in the afferent lymph draining the chancre. In this
context, VSG causes a polyclonal B-cell activation that triggers
the generation of auto-antibodies (Kazyumba et al., 1986) and
immune complexes (Lambert et al., 1981). The healing of the
chancre occurs simultaneously with an increase in lymphoblast
and surface immunoglobulin bearing cells in the afferent draining
lymph, while in the efferent lymph there is an increase in
lymphocytes bearing surface immunoglobulins (Mwangi et al.,
1996; Vincendeau and Bouteille, 2006). The effectiveness of the
immune system at this stage is limited since parasites cannot be
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eliminated due to their genetic versatility (Barry and Emergy,
1984). Then, differentiation to stumpy forms occur (Vincendeau
and Bouteille, 2006).
Cytokines and Chemokines
Trypanosomes are prone to activate the innate immune
system early in infection, a mechanism that affects B- and
T-cell responses to parasite antigens, including VSG as well
as many other surface and intracellular antigens like cell-
free DNA. For example, the activation of macrophages, as
well as of additional antigen presenting cells, are dramatically
altered in trypanosome infected tissues leading to a highly
polarized Th1 proinflammatory cytokine profile that includes
TNF-α, IL-6 and NO production and probably IL-1 and
IL-12 (Figure 4, reviewed by Mansfield and Paulnock,
2005).
The first evidence of the dysregulation of the cytokine network
that occurs in HAT is the induction by VSG of TNF-α (over)
production by macrophages (Rouzer and Cerami, 1980; Tachado
and Schofield, 1994; Okomo-Assoumou et al., 1995; Magez
et al., 2002). High levels of TNF-α and patent inflammatory
signs then occur in the early phase of human trypanosomiasis,
as well as during major neurologic manifestations in the late
phase (Okomo-Assoumou et al., 1995). This cytokine plays a
role on activation, proliferation and differentiation of B cells
(Rouzer and Cerami, 1980; Roldán et al., 1992), triggering a
cascade of events leading to elimination of parasites (Lucas
et al., 1993). At the clinical level, TNF-α induces fever, asthenia,
cachexia, and hypertriglyceridemia (Vincendeau and Bouteille,
2006); additionally, increased serum TNF-α levels contribute to
the hypergammaglobulinemia observed in trypanosomiasis.
On the other hand, interferon-gamma (IFN-γ) has a key role
in relative resistance to African trypanosomes. This cytokine is
transiently released primarily by parasite antigen activated Th1
cells, together with natural killer cells at earlier time points
in infection, activated by the TLTF released by the parasites.
Additionally, TGF-β, which has immunosuppressive effects, is
secreted by CD8 T cells also activated by the TLTF released by
trypanosomes (Olsson et al., 1991; Vaidya et al., 1997; reviewed
by Mansfield and Paulnock, 2005).
All in all, the parasite is capable of interfering with the
cytokine network, and can use cytokines as growth factors. By
doing that, trypanosomes modify the effector functions of the
immune system (Hide et al., 2004). Moreover, in the CNS of
T. b. brucei-infected animals, chemokines favor macrophage
and lymphocyte recruitment to areas where their activity might
induce additional alterations (Buguet et al., 1993, 2001; Lundkvist
et al., 2004). These results together with the fact that TNF-α RNA
transcripts have been described in the CNS and that intracerebral
infusion of soluble type I TNF-α receptor reduced trypanosome-
induced neurodegeneration (Quan et al., 2003), suggest that
TNF-α production could play a role in CNS disorders and that
TNF-α and other cytokines might contribute to the generation of
somnogenic molecules such as IL-1 (Pentreath et al., 1994).
CONCLUSION
Antigenic variation is one of several resources by which
trypanosomes manipulate their hosts. VSG of trypanosomes
constitutes the main antigenic molecule exposed in the surface
of these blood parasites. The mechanisms by which antigen
switching occurs are sophisticated and are likely to contribute to
infection chronicity. Coat renewal by VSG-switch is a strategy
by which the parasite successfully eludes the immune system,
avoids the action of blood-borne antibodies, and continues to
successfully infect the human host. Therefore, the effectiveness
of the immune system is limited and the parasite remains in the
bloodstream long enough to permit transmission to a new host,
either blood-sucking insects or human via blood–blood contact.
Superimposed upon antigen switching, the density-dependent
production of cell-cycle arrested parasite transmission stages
limits the infection and ensures parasite spread to new hosts
via the bite of blood feeding tsetse flies, thus contributing to
trypanosome infection transmission. Neither antigen switching
nor developmental progression to transmission stages is driven
by the host. However, the human host contributes to the infection
dynamics through the selection of distinct antigen types,
his/her genetic susceptibility (trypanotolerance) and the potential
influence of host-dependent effects on parasite pathogenicity.
Although further activation of innate immunity and cytokine and
chemokine secretion foster the successful clearance of the parasite
by the human host, the interaction between the human host and
the parasite is extremely active and leads to responses that need
multiple control sites to develop appropriately. The complexity
of the involved events reveals that trypanosomes use a focused
strategy that questions the existence of a truly developed human
host response.
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